Humana Posts $0.70 Adjusted Loss but Raises Full-Year 2026 Adjusted EPS Guidance to $9.50
Humana (HUM) reported a $0.70 adjusted loss for Q3 2026 but raised its full-year 2026 adjusted EPS guidance to at least $9.50. GAAP EPS was $1.33, down from $3.60 a year earlier. Revenue increased to $41.155 billion, up from $32.697 billion. The company cited valuation adjustments and strategic developments as key factors.
How this was made
The 30-second read
Why it matters
Guidance raise suggests improved earnings expectations, but adjusted loss highlights ongoing margin pressure.
Market read
Earnings and guidance update for a large‑cap insurer, directly relevant to equity traders and sector analysts.
What to watch
Regulatory star‑rating challenges and potential CMS bonus reductions remain significant risk factors.
Background
Humana released its Q3 2026 results and updated full‑year guidance via an 8‑K filing.
Ticker impact
Humana raised FY 2026 adjusted EPS guidance to at least $9.50 and GAAP EPS guidance to at least $15.09, while reporting a Q3 adjusted loss of $0.70 per share.
potential modest upside as investors price in higher future earnings
Guidance lifts set a higher earnings floor, but the adjusted loss signals margin pressure, leading to mixed but generally positive bias.
Market effects
Higher guidance may lift other health‑insurance peers as investors reassess earnings outlooks.
U.S. healthcare sector could see modest gains in the afternoon session.
Limited to U.S. markets; no direct global ripple.
Counterpoint
The adjusted loss and star‑rating headwinds could outweigh guidance benefits, prompting a short‑term pullback.
Key entities
- CompanyHumana Inc.
U.S. health‑insurance provider reporting earnings and guidance.
- InvestorHPS Investment Partners
BlackRock subsidiary involved in Humana's new joint venture.
